Latest revenue
$904.0M
as of 2026-03-31
Latest net income
$68.0M
as of 2026-03-31
Net margin
7.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $4.31B
- Enterprise value
- $4.31B
- P/E (trailing)
- 13.0×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 2.2%
- 52-wk high
- $86.43
- 52-wk low
- $58.33
- Beta
- —
- Shares out
- 51.6M
5-year trend
About CBT
Business description and risk factors will appear here once CBT's latest filing is fully ingested.
Profitability
Gross margin
25.3%
5.3%Operating margin
16.7%
8.8%Net margin
8.9%
6.3%Return on equity
21.4%
19.9%Return on assets
8.7%
14.7%Leverage
Debt / equity
1.46×
9.9%Long-term debt / equity
0.55×
27.6%Debt / assets
59.4%
4.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $904.0M | -3.4% | $68.0M | -27.7% | 7.5% |
Q4 2025 2025-12-31 | $849.0M | -11.1% | $73.0M | -21.5% | 8.6% |
Q3 2025 2025-09-30 | $899.0M | -10.2% | $43.0M | -68.6% | 4.8% |
Q2 2025 2025-06-30 | $923.0M | -9.2% | $101.0M | -7.3% | 10.9% |
Q1 2025 2025-03-31 | $936.0M | -8.1% | $94.0M | +11.9% | 10.0% |
Q4 2024 2024-12-31 | $955.0M | -0.3% | $93.0M | +86.0% | 9.7% |
Q3 2024 2024-09-30 | $1.00B | — | $137.0M | — | 13.7% |
Q2 2024 2024-06-30 | $1.02B | +5.0% | $109.0M | +32.9% | 10.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Miscellaneous Chemical Products · SIC 2890
Your notes
Keep private notes on CBT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$9.1M
Net activity
−$9.1M
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CBT
Institutional value
$1.73B
Total shares held
24.1M
Distinct holders
251
-111 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6.6M | $498.3M | -8.9K (-0.1%) | Trimmed |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.1M | $235.1M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.3M | $175.0M | — | New |
| 4 | DIMENSIONAL FUND ADVISORS LP | 1.7M | $131.3M | +79.5K (+4.8%) | Added |
| 5 | SEI INVESTMENTS CO | 1.1M | $79.2M | +64.1K (+6.5%) | Added |
| 6 | Invesco Ltd. | 640.1K | $48.2M | +154.3K (+31.8%) | Added |
| 7 | Bank of New York Mellon Corp | 634.2K | $47.8M | -1.7K (-0.3%) | Trimmed |
| 8 | Capital Research Global Investors | 462.7K | $34.8M | +0 (+0.0%) | No change |
| 9 | Lightrock Netherlands B.V. | 422.3K | $30.7M | -35.5K (-7.8%) | Trimmed |
| 10 | ProShare Advisors LLC | 366.3K | $27.6M | +349.9K (+2125.5%) | Added |
| 11 | VANGUARD FIDUCIARY TRUST CO | 363.4K | $27.4M | — | New |
| 12 | NEW YORK STATE COMMON RETIREMENT FUND | 338.1K | $25.5M | +47.4K (+16.3%) | Added |
| 13 | UBS Group AG | 287.5K | $21.6M | -326.7K (-53.2%) | Trimmed |
| 14 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | 286.0K | $21.3M | +0 (+0.0%) | No change |
| 15 | Fiera Capital Corp | 225.5K | $17.0M | +12.2K (+5.7%) | Added |
| 16 | Leeward Investments, LLC - MA | 224.7K | $16.9M | -5.4K (-2.3%) | Trimmed |
| 17 | EASTERN BANK | 222.1K | $16.7M | -13.3K (-5.6%) | Trimmed |
| 18 | WELLS FARGO & COMPANY/MN | 221.5K | $16.7M | -23.9K (-9.8%) | Trimmed |
| 19 | ENVESTNET ASSET MANAGEMENT INC | 180.8K | $13.6M | +12.3K (+7.3%) | Added |
| 20 | PRINCIPAL FINANCIAL GROUP INC | 177.4K | $13.4M | +10.8K (+6.5%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CBT's latest filing finishes processing.